NTRK1 and acute myeloid leukemia: Though mutation of receptor tyrosine kinases (RTK) like FLT3 has been suggested to be essential for AML, the recent report in Cell from Welch and colleagues on genomic screening of mutations in AML indicate that less than half of AML patients have a RTK mutation suggesting that other mechanisms are necessary to activate leukemic signaling pathways (32).